Skip to main content

Table 4 adverse event

From: Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

Adverse event

Group A (n = 45)

Group B (n = 45)

P value

G1

G2

G3

Any grade (%)

G2/G3 (%)

G1

G2

G3

Any grade (%)

G2/G3 (%)

Any grade

G2/G3

Any adverse event

27

8

5

40 (89%)

13 (29%)

15

24

6

45 (100%)

30 (67%)

0.056

0.001

Anemia

13

1

0

14 (31%)

1 (2%)

21

2

0

23 (51%)

2 (4%)

0.086

1.000

Leukopenia

7

2

0

9 (20%)

2 (4%)

12

2

0

14 (31%)

2 (4%)

0.334

1.000

Neutropenia

9

1

0

10 (22%)

1 (2%)

7

0

0

7 (16%)

0 (0%)

0.591

1.000

Thrombocytopenia

7

0

0

7 (16%)

0 (0%)

15

0

0

15 (33%)

0 (0%)

0.085

****

Elevation of AST

12

1

1

14 (31%)

2 (4%)

12

0

0

12 (27%)

0 (0%)

0.816

0.494

Elevation of ALT

12

2

0

14 (31%)

2 (4%)

13

1

0

14 (31%)

1 (2%)

1.000

1.000

Elevation of LDH

5

0

0

5 (11%)

0 (0%)

10

0

0

10 (22%)

0 (0%)

0.258

****

Elevation of bilirubin

15

1

0

16 (36%)

1 (2%)

14

6

1

21 (47%)

7 (16%)

0.392

0.058

Elevation of creatinine

3

0

0

3 (7%)

0 (0%)

5

0

0

5 (11%)

0 (0%)

0.714

****

Anorexia

8

0

1

9 (20%)

1 (2%)

17

4

1

22 (49%)

5 (11%)

0.007

0.203

Nausea

12

0

0

12 (27%)

0 (0%)

13

4

0

17 (38%)

4 (9%)

0.367

0.117

Vomiting

4

0

0

4 (9%)

0 (0%)

6

1

0

7 (16%)

1 (2%)

0.522

1.000

Diarrhea

5

3

0

8 (18%)

3 (7%)

10

2

1

13 (29%)

3 (7%)

0.319

1.000

Stomatitis

9

0

0

9 (20%)

0 (0%)

9

2

1

12 (27%)

3 (7%)

0.619

0.242

Fatigue

4

0

0

4 (9%)

0 (0%)

5

1

0

6 (13%)

1 (2%)

0.739

1.000

Skin symptoms

4

0

1

5 (11%)

1 (2%)

13

6

1

20 (44%)

7 (16%)

0.001

0.058

Keratinitis/conjunctivitis

0

0

0

0 (0%)

0 (0%)

5

2

0

7 (16%)

2 (4%)

0.012

0.494

  1. **** incalculable